.jpg)
.png)
All
The National Lipid Association is excited to announce a month-long extravaganza of virtual education, LipidPALOOZA, launching this September to celebrate National Cholesterol Education Month. There will be a variety of activities spread throughout the entire month and best of all, they will be... more
Dr. Patrick McBride, Associate Dean for Students at University of Wisconsin School of Medicine and Public Health, was recently honored with the Distinguished Achievement Award at the National Lipid Association’s 2015 Annual Sessions. The annual award is the highest honor conferred by the National... more
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although approximately 20% of the population has elevated Lp(a) levels (≥ 50 mg/dL or 125 nmol/L), there are currently no approved targeted medical treatments available. Lp(a) has a unique... more
Discuss this article at www.lipid.org/lipidspin Diabetes mellitus (DM) is a leading cause of cardiovascular disease (CVD) and its associated morbidity and mortality.(1) DM confers the highest lifetime risk of any individual risk factor for developing cardiovascular disease. Although morbidity... more
After years of thoughtful planning and development, the National Lipid Association (NLA) recently released its first edition of the Annual Summary of Clinical Lipidology. The first issue, which was published as a supplement to the November/December issue of the Journal... more
Heart disease is the biggest killer in the country. But an argument is raging about a popular way of preventing it. Wall Street Journal - January 23, 2012
Be sure to read the latest JCL Roundtable featuring Lauren Williams, RDN, Lynne T. Braun, PhD, CNP, FNLA, Joseph J. Saseen, PharmD, FNLA, and John R. Guyton, MD, FNLA discussing the importance of the lipidology team. Abstract Clinical lipidology practice works best when implemented by a... more
Introduction Despite significant advances in detection and treatment, cardiovascular disease (CVD) is the leading cause of death and disability worldwide.(1,2) The 3-hydroxymethylglutaryl coenzyme A (HMGCoA) reductase inhibitors (aka statins) ushered in a new era for prevention of cardiovascular... more
On July 24, 2015, the United States Food and Drug Administration approved the clinical use of the PCSK9 inhibitor, alirocumab, as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease who... more